{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T19:06:46Z","timestamp":1791745606607,"version":"4.3.4"},"reference-count":201,"publisher":"Informa UK Limited","issue":"12","license":[{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Nanomedicine"],"published-print":{"date-parts":[[2026,6,18]]},"DOI":"10.1080\/17435889.2026.2681556","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T12:42:19Z","timestamp":1780490539000},"page":"1797-1826","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["Impact of nanocarrier mediated drug delivery systems: a deep dive into therapeutics and clinical management of breast cancer"],"prefix":"10.1080","volume":"21","author":[{"given":"Sana","family":"Hanif","sequence":"first","affiliation":[{"name":"The University of Lahore","place":["Lahore, Pakistan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nariman","family":"Shahid","sequence":"additional","affiliation":[{"name":"The University of Lahore","place":["Lahore, Pakistan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Iqbal","sequence":"additional","affiliation":[{"name":"The University of Lahore","place":["Lahore, Pakistan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saleha","family":"Yasir","sequence":"additional","affiliation":[{"name":"The University of Lahore","place":["Lahore, Pakistan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hafiz","family":"Arfat Idrees","sequence":"additional","affiliation":[{"name":"University of Pavia","place":["Pavia, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Irshad","family":"Farooq","sequence":"additional","affiliation":[{"name":"University of Toyama","place":["Toyama, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Rai","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital, Harvard Medical School","place":["Boston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Ali Syed","sequence":"additional","affiliation":[{"name":"Government College University","place":["Lahore, Pakistan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sobia","family":"Noreen","sequence":"additional","affiliation":[{"name":"University of Illinois Cancer Center","place":["Chicago (UIC), USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,6,3]]},"reference":[{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-025-13730-y"},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.colsurfb.2025.114805"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-018-0165-1"},{"key":"e_1_3_6_6_1","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2021.694218"},{"key":"e_1_3_6_7_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI130323"},{"key":"e_1_3_6_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00828-5"},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molstruc.2023.135196"},{"key":"e_1_3_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104646"},{"key":"e_1_3_6_11_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnano.2025.1548593"},{"key":"e_1_3_6_12_1","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S242490"},{"key":"e_1_3_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2019.03.020"},{"key":"e_1_3_6_14_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph14060557"},{"key":"e_1_3_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.sjbs.2023.103874"},{"key":"e_1_3_6_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/smtd.202300230"},{"key":"e_1_3_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2025.02.026"},{"key":"e_1_3_6_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2017.04.010"},{"key":"e_1_3_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2025.102885"},{"key":"e_1_3_6_20_1","doi-asserted-by":"publisher","DOI":"10.33590\/oncolamj\/DAHP8382"},{"key":"e_1_3_6_21_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16020466"},{"key":"e_1_3_6_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-024-03227-6"},{"key":"e_1_3_6_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/mef2.70013"},{"key":"e_1_3_6_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/PCR.0000000000000239"},{"key":"e_1_3_6_25_1","volume-title":"WHO classifcation of tumours series","author":"Rakha EARFJ","year":"2019","unstructured":"Rakha EARFJ, Sasano H, Wu Y. WHO classifcation of tumours editorial board: Breast tumours. In: WHO classifcation of tumours series. 5th ed. Lyon (France): International Agency for Research on Cancer; 2019.","edition":"5"},{"key":"e_1_3_6_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz235"},{"key":"e_1_3_6_27_1","doi-asserted-by":"publisher","DOI":"10.1159\/000499931"},{"key":"e_1_3_6_28_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.20751"},{"key":"e_1_3_6_29_1","doi-asserted-by":"publisher","DOI":"10.3390\/medicina61071280"},{"key":"e_1_3_6_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30112-1"},{"key":"e_1_3_6_31_1","doi-asserted-by":"publisher","DOI":"10.2147\/BCTT.S176514"},{"key":"e_1_3_6_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-025-02542-y"},{"key":"e_1_3_6_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2025.145377"},{"key":"e_1_3_6_34_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.6650"},{"key":"e_1_3_6_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cclet.2024.110045"},{"key":"e_1_3_6_36_1","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S333657"},{"key":"e_1_3_6_37_1","doi-asserted-by":"publisher","DOI":"10.2174\/1871520619666191022175003"},{"key":"e_1_3_6_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2025.118224"},{"key":"e_1_3_6_39_1","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S289443"},{"key":"e_1_3_6_40_1","doi-asserted-by":"publisher","DOI":"10.1080\/1061186X.2018.1437920"},{"key":"e_1_3_6_41_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24076615"},{"key":"e_1_3_6_42_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27041372"},{"key":"e_1_3_6_43_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23084249"},{"issue":"4","key":"e_1_3_6_44_1","first-page":"447","article-title":"Heat-targeted drug delivery: a promising approach for organsparing treatment of bladder cancer THERMODOX\u00ae","volume":"71","author":"Aminsharifi A","year":"2018","unstructured":"Aminsharifi A, Brousell SC, Chang A, et al. Heat-targeted drug delivery: a promising approach for organsparing treatment of bladder cancer THERMODOX\u00ae. Archivos Espanoles de Urologia. 2018;71(4):447\u2013452.","journal-title":"Archivos Espanoles de Urologia"},{"key":"e_1_3_6_45_1","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/581363"},{"key":"e_1_3_6_46_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.9b00583"},{"key":"e_1_3_6_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2019.104398"},{"key":"e_1_3_6_48_1","doi-asserted-by":"publisher","DOI":"10.2174\/0929867327666200819115403"},{"key":"e_1_3_6_49_1","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S272529"},{"key":"e_1_3_6_50_1","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2020-0258"},{"key":"e_1_3_6_51_1","doi-asserted-by":"publisher","DOI":"10.1002\/bab.2253"},{"key":"e_1_3_6_52_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics9020012"},{"key":"e_1_3_6_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chemphyslip.2019.104785"},{"key":"e_1_3_6_54_1","doi-asserted-by":"publisher","DOI":"10.3390\/polym14183886"},{"key":"e_1_3_6_55_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27030860"},{"key":"e_1_3_6_56_1","doi-asserted-by":"publisher","DOI":"10.1080\/03639045.2021.1934873"},{"issue":"1","key":"e_1_3_6_57_1","first-page":"19","article-title":"Preparation, characterization and evaluation of cytotoxic activity of tamoxifen bound liposomes against breast cancer cell line","volume":"21","author":"Shafaa M","year":"2020","unstructured":"Shafaa M. Preparation, characterization and evaluation of cytotoxic activity of tamoxifen bound liposomes against breast cancer cell line. Egypt J Biomed Eng Biophys. 2020;21(1):19\u201331.","journal-title":"Egypt J Biomed Eng Biophys"},{"key":"e_1_3_6_58_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-020-01743-8"},{"key":"e_1_3_6_59_1","doi-asserted-by":"publisher","DOI":"10.1080\/1061186X.2018.1428809"},{"key":"e_1_3_6_60_1","doi-asserted-by":"publisher","DOI":"10.1039\/D2NR06215A"},{"key":"e_1_3_6_61_1","doi-asserted-by":"publisher","DOI":"10.1177\/0883911520913906"},{"key":"e_1_3_6_62_1","doi-asserted-by":"publisher","DOI":"10.2217\/nnm-2023-0318"},{"key":"e_1_3_6_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31709-X"},{"key":"e_1_3_6_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2022.104146"},{"key":"e_1_3_6_65_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-81701-x"},{"key":"e_1_3_6_66_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12070666"},{"key":"e_1_3_6_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2017.03.008"},{"key":"e_1_3_6_68_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics11020063"},{"key":"e_1_3_6_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2017.07.085"},{"key":"e_1_3_6_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.colsurfb.2019.110515"},{"key":"e_1_3_6_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.colsurfb.2018.10.007"},{"key":"e_1_3_6_72_1","doi-asserted-by":"publisher","DOI":"10.1080\/10837450.2018.1455698"},{"key":"e_1_3_6_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2019.03.039"},{"key":"e_1_3_6_74_1","doi-asserted-by":"publisher","DOI":"10.3390\/nano9091208"},{"key":"e_1_3_6_75_1","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S209325"},{"key":"e_1_3_6_76_1","volume-title":"Synthesis and characterization of PLGA-PEG thymoquinone nanoparticles and its cytotoxicity effects in tamoxifen-resistant breast cancer cells","author":"Ahmad R","year":"2020","unstructured":"Ahmad R, Kaus NHM, Hamid S. Synthesis and characterization of PLGA-PEG thymoquinone nanoparticles and its cytotoxicity effects in tamoxifen-resistant breast cancer cells. Cham, Switzerland: Springer Nature Switzerland (AG); 2020."},{"key":"e_1_3_6_77_1","doi-asserted-by":"publisher","DOI":"10.1080\/21691401.2017.1423495"},{"key":"e_1_3_6_78_1","doi-asserted-by":"publisher","DOI":"10.1002\/jbm.a.36360"},{"key":"e_1_3_6_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msec.2020.111046"},{"key":"e_1_3_6_80_1","doi-asserted-by":"publisher","DOI":"10.1080\/10717544.2022.2039804"},{"key":"e_1_3_6_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jare.2019.02.036"},{"key":"e_1_3_6_82_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-018-0392-8"},{"key":"e_1_3_6_83_1","doi-asserted-by":"publisher","DOI":"10.1002\/adtp.201900081"},{"key":"e_1_3_6_84_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-15648-y"},{"key":"e_1_3_6_85_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15071824"},{"key":"e_1_3_6_86_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2548"},{"key":"e_1_3_6_87_1","unstructured":"ClinicalTrials.gov. MM-398 (nanoliposomal Irinotecan nal-IRI) to determine tumor drug levels and to evaluate the feasibility of Ferumoxytol magnetic resonance imaging to measure tumor associated macrophages and to predict patient response to treatment. 2025 [2019 Nov 27; cited 2025 May 25]; Available from: https:\/\/clinicaltrials.gov\/study\/NCT01770353"},{"key":"e_1_3_6_88_1","unstructured":"ClinicalTrials.gov. A phase I study to evaluate the safety tolerability pharmacokinetics and preliminary efficacy of irinotecan liposome injection in patients with advanced breast cancer. 2025 [2024 Jul 26; cited 2025 May 25]; Available from: https:\/\/clinicaltrials.gov\/study\/NCT04728035"},{"key":"e_1_3_6_89_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.11.013"},{"key":"e_1_3_6_90_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.08.002"},{"key":"e_1_3_6_91_1","unstructured":"ClinicalTrials.gov. Neoadjuvant weekly Nab-Paclitaxel (Abraxane\u00ae) plus carboplatin followed by doxorubicin plus cyclophosphamide with bevacizumab added concurrently to chemotherapy for palpable and operable triple negative invasive breast cancer. 2025 [2013 Jan 04; cited 2025 25 May]; Available from: https:\/\/clinicaltrials.gov\/study\/NCT00777673"},{"key":"e_1_3_6_92_1","unstructured":"ClinicalTrials.gov. A randomized phase II trial of weekly nanoparticle albumin bound paclitaxel (nab-paclitaxel) (NSC-736631) with or without bevacizumab either preceded by or followed by Q 2\u00a0week doxorubicin (A)and cyclophosphamide (C) plus pegfilgrastim (PEG-G) as neoadjuvant therapy for inflammatory and locally advanced HER-2\/neu negative breast cancer. 2025 [2017 Jun 27; cited 2025 May 25]; Available from: https:\/\/clinicaltrials.gov\/study\/NCT00856492"},{"key":"e_1_3_6_93_1","unstructured":"ClinicalTrials.gov. Phase I\/II study of weekly abraxane and RAD001 in women with locally advanced or metastatic breast cancer. A> study of the cancer Institute of New Jersey Oncology Group (CINJOG). 2025 [2023 Sep 18; cited 2025 May 25]; Available from: https:\/\/clinicaltrials.gov\/study\/NCT00934895"},{"key":"e_1_3_6_94_1","unstructured":"ClinicalTrials.gov. Evaluate Trastuzumab plus standard chemotherapy Given before surgery in breast cancer patients with low HER 2 expression. 2025 [2018 Apr 23; cited 2025 25 May]; Available from: https:\/\/clinicaltrials.gov\/study\/NCT00944047"},{"key":"e_1_3_6_95_1","unstructured":"ClinicalTrials.gov. Phase II study of Panitumumab Nab-Paclitaxel and carboplatin for patients with primary inflammatory breast cancer (IBC) without HER2 overexpression. 2025 [2023 Mar 30; cited 2025 25 May]; Available from: https:\/\/clinicaltrials.gov\/study\/NCT01036087"},{"key":"e_1_3_6_96_1","unstructured":"ClinicalTrials.gov. A phase II study of Abraxane\u00ae and carboplatin as first-line treatment for \u201ctriple negative\u201d (Demonstrating No expression for estrogen progesterone or human epidermal growth factor receptor 2 (HER2)Receptors) metastatic breast cancer. 2025 [2014 Dec 15; cited 2025 May 25]; Available from: https:\/\/clinicaltrials.gov\/study\/NCT01207102"},{"key":"e_1_3_6_97_1","unstructured":"ClinicalTrials.gov. Adjuvant chemotherapy for elderly non frail patients with an increased risk for relapse of a primary carcinoma of the breast (ICE-II). 2025 [2016 Feb 10; cited 2025 May 25]; Available from: https:\/\/clinicaltrials.gov\/study\/NCT01204437"},{"key":"e_1_3_6_98_1","unstructured":"ClinicalTrials.gov. A phase I\/II clinical trial of the hypomethylating agent azacitidine (vidaza) with the nanoparticle albumin bound paclitaxel (Abraxane) in the treatment of patients with advanced or metastatic solid tumors and breast cancer. 2025 [2017 Jul 26; cited 2025 May 25]; Available from: https:\/\/clinicaltrials.gov\/study\/NCT00748553"},{"key":"e_1_3_6_99_1","unstructured":"Phase I. NCT (Neoadjuvant chemotherapy) w. weekly Abraxane in combination with Carboplatin & Bevacizumab in breast cancer. 2018 [cited 2023 Sep 13]."},{"key":"e_1_3_6_100_1","unstructured":"ClinicalTrials.gov. Combined targeted therapies for triple negative advanced breast cancer - a phase II trial of weekly nab-paclitaxel and bevacizumab followed by maintenance targeted therapy with bevacizumab and Erlotinib. 2025 2018 Dec 04; cited 2025 May 25]; Available from: https:\/\/clinicaltrials.gov\/study\/NCT00733408"},{"key":"e_1_3_6_101_1","unstructured":"ClinicalTrials.gov. Nanoparticle albumin-bound (NAB) paclitaxel\/cyclophosphamide in early-stage breast cancer. 2025 [2021 Nov 24; cited 2025 May 25]; Available from: https:\/\/clinicaltrials.gov\/study\/NCT00629499"},{"key":"e_1_3_6_102_1","unstructured":"ClinicalTrials.gov. A phase II study of carboplatin nanoparticle albumin-bound paclitaxel (ABI-007) and avastin as the first line therapy in metastatic breast cancer. 2025 [2017 Sep14; cited 2025 May 25]; Available from: https:\/\/clinicaltrials.gov\/study\/NCT00654836"},{"key":"e_1_3_6_103_1","unstructured":"ClinicalTrials.gov. Paclitaxel albumin-stabilized Nanoparticle formulation Gemcitabine and bevacizumab in treating patients with metastatic breast cancer. 2025 [2017 Apr 17; cited 2025 May 25]; Available from: https:\/\/clinicaltrials.gov\/study\/NCT00662129"},{"key":"e_1_3_6_104_1","unstructured":"ClinicalTrials.gov. Paclitaxel albumin-stabilized nanoparticle formulation in treating patients of different ages with metastatic breast cancer. [2025 Mar 19; cited 2025 25 May]; Available from: https:\/\/clinicaltrials.gov\/study\/NCT00609791"},{"key":"e_1_3_6_105_1","unstructured":"ClinicalTrials.gov. Capecitabine and paclitaxel (Albumin-stabilized Nanoparticle formulation) in treating women undergoing surgery for stage II or stage III breast cancer. 2021 Feb 17 [cited 2025]; Available from: https:\/\/clinicaltrials.gov\/study\/NCT00397761"},{"key":"e_1_3_6_106_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00289-024-05384-w"},{"key":"e_1_3_6_107_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-021-01174-y"},{"key":"e_1_3_6_108_1","doi-asserted-by":"publisher","DOI":"10.3390\/pr11041193"},{"key":"e_1_3_6_109_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.synthmet.2015.03.011"},{"key":"e_1_3_6_110_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.carbon.2025.119986"},{"key":"e_1_3_6_111_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioactmat.2020.09.006"},{"key":"e_1_3_6_112_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jphotobiol.2020.111902"},{"key":"e_1_3_6_113_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmmm.2019.04.058"},{"key":"e_1_3_6_114_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcis.2020.02.051"},{"key":"e_1_3_6_115_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msec.2019.02.096"},{"key":"e_1_3_6_116_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-66419-6"},{"key":"e_1_3_6_117_1","doi-asserted-by":"publisher","DOI":"10.1039\/D0RA06708C"},{"key":"e_1_3_6_118_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.arabjc.2018.04.012"},{"key":"e_1_3_6_119_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.colsurfa.2021.127609"},{"key":"e_1_3_6_120_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinorgbio.2021.111433"},{"key":"e_1_3_6_121_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2019.105070"},{"key":"e_1_3_6_122_1","doi-asserted-by":"publisher","DOI":"10.1039\/C9TB02711D"},{"key":"e_1_3_6_123_1","doi-asserted-by":"publisher","DOI":"10.1080\/00914037.2021.1925277"},{"key":"e_1_3_6_124_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msec.2021.112586"},{"key":"e_1_3_6_125_1","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2018.6334"},{"key":"e_1_3_6_126_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-26790-x"},{"key":"e_1_3_6_127_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12013-014-0363-0"},{"key":"e_1_3_6_128_1","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/5597681"},{"key":"e_1_3_6_129_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.8b01343"},{"key":"e_1_3_6_130_1","doi-asserted-by":"publisher","DOI":"10.7150\/ntno.51955"},{"key":"e_1_3_6_131_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11427-017-9274-9"},{"key":"e_1_3_6_132_1","doi-asserted-by":"publisher","DOI":"10.4172\/pharmaceutical-sciences.1000153"},{"key":"e_1_3_6_133_1","doi-asserted-by":"publisher","DOI":"10.1088\/1361-6528\/ac5f9a"},{"key":"e_1_3_6_134_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.arabjc.2021.103344"},{"key":"e_1_3_6_135_1","doi-asserted-by":"publisher","DOI":"10.1039\/D0RA01589J"},{"key":"e_1_3_6_136_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2020.101769"},{"key":"e_1_3_6_137_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2017.07.003"},{"key":"e_1_3_6_138_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.111053"},{"key":"e_1_3_6_139_1","doi-asserted-by":"publisher","DOI":"10.1039\/C7PY01701D"},{"key":"e_1_3_6_140_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12645-023-00160-3"},{"key":"e_1_3_6_141_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules23071578"},{"key":"e_1_3_6_142_1","doi-asserted-by":"publisher","DOI":"10.34172\/apb.2023.033"},{"key":"e_1_3_6_143_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-020-00604-7"},{"key":"e_1_3_6_144_1","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/6253978"},{"key":"e_1_3_6_145_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.614290"},{"key":"e_1_3_6_146_1","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/6009309"},{"key":"e_1_3_6_147_1","doi-asserted-by":"publisher","DOI":"10.1088\/1361-6528\/abaf81"},{"key":"e_1_3_6_148_1","doi-asserted-by":"publisher","DOI":"10.3897\/pharmacia.69.e85390"},{"issue":"12","key":"e_1_3_6_149_1","first-page":"5185","article-title":"Folate-targeted nanostructured lipid carriers (NLCs) enhance (letrozol) efficacy in MCF-7 breast cancer cells","volume":"17","author":"Sabzichi M","year":"2016","unstructured":"Sabzichi M, Mohammadian J, Khosroushahi AY, et al. Folate-targeted nanostructured lipid carriers (NLCs) enhance (letrozol) efficacy in MCF-7 breast cancer cells. Asian Pac J Cancer Prev Apjcp. 2016;17(12):5185.","journal-title":"Asian Pac J Cancer Prev Apjcp"},{"key":"e_1_3_6_150_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27248838"},{"key":"e_1_3_6_151_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.carbpol.2022.119401"},{"key":"e_1_3_6_152_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12111107"},{"key":"e_1_3_6_153_1","doi-asserted-by":"publisher","DOI":"10.3390\/life12091369"},{"key":"e_1_3_6_154_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2018.11.110"},{"key":"e_1_3_6_155_1","doi-asserted-by":"publisher","DOI":"10.4314\/tjpr.v19i1.2"},{"key":"e_1_3_6_156_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.colsurfb.2017.09.008"},{"key":"e_1_3_6_157_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2022.103886"},{"key":"e_1_3_6_158_1","doi-asserted-by":"publisher","DOI":"10.3390\/polym14122510"},{"key":"e_1_3_6_159_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-022-01599-9"},{"key":"e_1_3_6_160_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2019.119420"},{"key":"e_1_3_6_161_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2012.08.042"},{"key":"e_1_3_6_162_1","doi-asserted-by":"publisher","DOI":"10.1088\/1758-5090\/aca5b8"},{"key":"e_1_3_6_163_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-025-06306-8"},{"key":"e_1_3_6_164_1","doi-asserted-by":"publisher","DOI":"10.1002\/anie.202417518"},{"key":"e_1_3_6_165_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15020398"},{"key":"e_1_3_6_166_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep23179"},{"key":"e_1_3_6_167_1","first-page":"135","volume-title":"Dendrimers for drug delivery","author":"Das N","year":"2018","unstructured":"Das N, Sharma PA, Seth A, et al. An overview of dendrimers and their biomedical applications. In: Tekade RK, Sharma AJK, Heservari JG, editors. Dendrimers for drug delivery. Oakville (Canada): Apple Academic Press; 2018. p. 135\u2013206."},{"key":"e_1_3_6_168_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2020.03.009"},{"key":"e_1_3_6_169_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2023.05.021"},{"key":"e_1_3_6_170_1","doi-asserted-by":"publisher","DOI":"10.1096\/fj.04-2747rev"},{"key":"e_1_3_6_171_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2010.04.009"},{"key":"e_1_3_6_172_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15082065"},{"key":"e_1_3_6_173_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molliq.2023.121908"},{"key":"e_1_3_6_174_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.arabjc.2021.103426"},{"key":"e_1_3_6_175_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnano.2025.1765965"},{"key":"e_1_3_6_176_1","doi-asserted-by":"publisher","DOI":"10.2174\/1389201023666211230113658"},{"key":"e_1_3_6_177_1","doi-asserted-by":"publisher","DOI":"10.3390\/bioengineering9070320"},{"key":"e_1_3_6_178_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2020.02.275"},{"key":"e_1_3_6_179_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14071486"},{"key":"e_1_3_6_180_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nano.2016.03.003"},{"key":"e_1_3_6_181_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpx.2025.100353"},{"key":"e_1_3_6_182_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioactmat.2025.09.012"},{"key":"e_1_3_6_183_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-011415"},{"key":"e_1_3_6_184_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1389971"},{"key":"e_1_3_6_185_1","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202303582"},{"key":"e_1_3_6_186_1","doi-asserted-by":"publisher","DOI":"10.3390\/jfb15110324"},{"key":"e_1_3_6_187_1","doi-asserted-by":"publisher","DOI":"10.32604\/or.2025.066624"},{"key":"e_1_3_6_188_1","doi-asserted-by":"publisher","DOI":"10.3390\/nano12244494"},{"key":"e_1_3_6_189_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-02108-4"},{"issue":"11","key":"e_1_3_6_190_1","first-page":"1663","article-title":"Nanotechnology in cancer drug delivery: innovations and clinical applications","volume":"31","author":"Alavandar A","year":"2024","unstructured":"Alavandar A, Pakale PV, Ansari MAQ, et al. Nanotechnology in cancer drug delivery: innovations and clinical applications. J Popul Ther Clin Pharmacol. 2024;31(11):1663\u20131672.","journal-title":"J Popul Ther Clin Pharmacol"},{"key":"e_1_3_6_191_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2022.06.095"},{"key":"e_1_3_6_192_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmedt.2022.893056"},{"key":"e_1_3_6_193_1","doi-asserted-by":"publisher","DOI":"10.1586\/14737140.8.3.331"},{"key":"e_1_3_6_194_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ipha.2025.08.001"},{"key":"e_1_3_6_195_1","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202405618"},{"key":"e_1_3_6_196_1","doi-asserted-by":"publisher","DOI":"10.1002\/adma.201901989"},{"key":"e_1_3_6_197_1","doi-asserted-by":"publisher","DOI":"10.1039\/C8GC01248B"},{"key":"e_1_3_6_198_1","doi-asserted-by":"publisher","DOI":"10.1201\/9781003482826-1"},{"key":"e_1_3_6_199_1","doi-asserted-by":"publisher","DOI":"10.1002\/VIW.20200190"},{"key":"e_1_3_6_200_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11051-025-06293-3"},{"key":"e_1_3_6_201_1","doi-asserted-by":"publisher","DOI":"10.3390\/chemengineering9030056"},{"key":"e_1_3_6_202_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.actbio.2018.09.047"},{"key":"e_1_3_6_203_1","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2019.00423"}],"container-title":["Nanomedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17435889.2026.2681556","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/17435889.2026.2681556","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17435889.2026.2681556","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T07:16:22Z","timestamp":1787123782000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17435889.2026.2681556"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,3]]},"references-count":201,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,6,18]]}},"alternative-id":["10.1080\/17435889.2026.2681556"],"URL":"https:\/\/doi.org\/10.1080\/17435889.2026.2681556","relation":{},"ISSN":["1743-5889","1748-6963"],"issn-type":[{"value":"1743-5889","type":"print"},{"value":"1748-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,3]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=innm20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=innm20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-12-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}